ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies

被引：1

作者：

Bonnet, Clement ^{[1
]}

Beinse, Guillaume ^{[1
]}

Cabel, Luc ^{[1
]}

Cochereau, Delphine ^{[1
]}

Lavaud, Pernelle ^{[1
]}

Rochefort, Pauline ^{[1
]}

Tabouret, Emeline ^{[1
]}

Turpin, Anthony ^{[1
]}

Verlingue, Loic ^{[1
]}

Vicier, Cecile ^{[1
]}

Massard, Christophe ^{[1
,2
]}

机构：

[1] AERIO, 149 Ave Maine, F-75014 Paris, France

[2] Gustave Roussy, DITEP, F-94805 Villejuif, France

来源：

BULLETIN DU CANCER | 2016年 / 103卷 / 06期

关键词：

Immunotherapies; Targeted therapies; Personalized medicine; Early phase studies; ADVANCED BREAST-CANCER; RENAL-CELL CARCINOMA; EVEROLIMUS; PALBOCICLIB; NIVOLUMAB; MELANOMA;

D O I：

10.1016/j.bulcan.2016.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The ESMO/ECC congress (European Society for Medical Oncology/European Cancer Congress) took place in Vienna, Austria, September 25-29. The main topic of the conference was immunotherapies especially in advanced kidney cancer with nivolumab in phase III and in metastatic lung cancer with atezolizumab in phase II. Targeted therapies were also highlighted with cabozantinib proposed in advanced renal cancer or everolimus in differenciated neuroendocrine tumors grade 1 or 2. Furthermore the current challenges remain unchanged: improving patients' care through better selection and finding biomarkers using simple samples (blood or urine). Also early phases and personalized medicine found their place in the different presentations and were highlighted largely bringing new approaches in the treatment of metastatic patients.

引用

页码：594 / 603

页数：10

共 11 条

[1] Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses [J].

Brodowicz, T. ;

Lang, I. ;

Kahan, Z. ;

Greil, R. ;

Beslija, S. ;

Stemmer, S. M. ;

Kaufman, B. ;

Petruzelka, L. ;

Eniu, A. ;

Anghel, R. ;

Koynov, K. ;

Vrbanec, D. ;

Pienkowski, T. ;

Melichar, B. ;

Spanik, S. ;

Ahlers, S. ;

Messinger, D. ;

Inbar, M. J. ;

Zielinski, C. .

BRITISH JOURNAL OF CANCER, 2014, 111 (11) :2051-2057

[2] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[3]

Demetri G.D., 2015, J. Clin. Oncol

[4]

Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586

[5] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].

Finn, Richard S. ;

Crown, John P. ;

Lang, Istvan ;

Boer, Katalin ;

Bondarenko, Igor M. ;

Kulyk, Sergey O. ;

Ettl, Johannes ;

Patel, Ravindranath ;

Pinter, Tamas ;

Schmidt, Marcus ;

Shparyk, Yaroslav ;

Thummala, Anu R. ;

Voytko, Nataliya L. ;

Fowst, Camilla ;

Huang, Xin ;

Kim, Sindy T. ;

Randolph, Sophia ;

Slamon, Dennis J. .

LANCET ONCOLOGY, 2015, 16 (01) :25-35

[6]

Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]

[7] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Macpherson, Euan ;

Watkins, Claire ;

Carmichael, James ;

Matulonis, Ursula .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392

[8] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Escudier, B. ;

McDermott, D. F. ;

George, S. ;

Hammers, H. J. ;

Srinivas, S. ;

Tykodi, S. S. ;

Sosman, J. A. ;

Procopio, G. ;

Plimack, E. R. ;

Castellano, D. ;

Choueiri, T. K. ;

Gurney, H. ;

Donskov, F. ;

Bono, P. ;

Wagstaff, J. ;

Gauler, T. C. ;

Ueda, T. ;

Tomita, Y. ;

Schutz, F. A. ;

Kollmannsberger, C. ;

Larkin, J. ;

Ravaud, A. ;

Simon, J. S. ;

Xu, L-A ;

Waxman, I. M. ;

Sharma, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1803-1813

[9] Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib [J].

Robert, Caroline ;

Karaszewska, Boguslawa ;

Schachter, Jacob ;

Rutkowski, Piotr ;

Mackiewicz, Andrzej ;

Stroiakovski, Daniil ;

Lichinitser, Michael ;

Dummer, Reinhard ;

Grange, Florent ;

Mortier, Laurent ;

Chiarion-Sileni, Vanna ;

Drucis, Kamil ;

Krajsova, Ivana ;

Hauschild, Axel ;

Lorigan, Paul ;

Wolter, Pascal ;

Long, Georgina V. ;

Flaherty, Keith ;

Nathan, Paul ;

Ribas, Antoni ;

Martin, Anne-Marie ;

Sun, Peng ;

Crist, Wendy ;

Legos, Jeff ;

Rubin, Stephen D. ;

Little, Shonda M. ;

Schadendorf, Dirk .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (01) :30-39

[10] Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer [J].

Turner, Nicholas C. ;

Ro, Jungsil ;

Andre, Fabrice ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Loibl, Sibylle ;

Bartlett, Cynthia Huang ;

Zhang, Ke ;

Giorgetti, Carla ;

Randolph, Sophia ;

Koehler, Maria ;

Cristofanilli, Massimo .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) :209-219

← 1 2 →